CNR2 and inflammatory bowel disease: While selective CB2 agonists, such as JWH-133, have been extensively studied in preclinical in vitro and in vivo models to investigate CB2-mediated immunomodulation [7,49], their direct therapeutic use in IBD has yet to be established.